Literature DB >> 20142525

Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin.

Brendan J Kelley1, Wael Haidar, Bradley F Boeve, Matt Baker, Maria Shiung, David S Knopman, Rosa Rademakers, Mike Hutton, Jennifer Adamson, Karen M Kuntz, Dennis W Dickson, Joseph E Parisi, Glenn E Smith, Ronald C Petersen.   

Abstract

OBJECTIVE: To characterize a kindred with a familial neurodegenerative disorder associated with a mutation in progranulin (PGRN), with emphasis on the unique clinical features in this kindred.
DESIGN: Antemortem and postmortem characterization of a kindred with a familial neurodegenerative disorder.
SETTING: Multispecialty group academic medical center. PATIENTS: Affected members of a kindred with dementia with or without parkinsonism associated with a unique mutation in PGRN. MAIN OUTCOME MEASURE: Genotype-phenotype correlation.
RESULTS: Of 10 affected individuals identified, 6 presented with early amnestic symptoms which resulted in initial diagnoses of Alzheimer disease or amnestic mild cognitive impairment. Some individuals presented with features characteristic of frontotemporal dementia. Mean age at onset was substantially younger in generation III (75.8 years; range, 69-80 years) than in generation II (60.7 years; range, 55-66 years). The pattern of cerebral atrophy varied widely in the affected individuals. Neuropathologic features in 6 individuals included frontotemporal lobar degeneration with ubiquitin-positive neuronal cytoplasmic and intranuclear inclusions (FTLD-U with NII). PGRN analysis revealed a single base pair deletion in exon 2 (c.154delA), which caused a frameshift (p.Thr52HisfsX2) and, therefore, creation of a premature termination codon and a likely null allele.
CONCLUSIONS: In this large kindred, most affected individuals had clinical presentations that resembled Alzheimer disease or amnestic mild cognitive impairment associated with a mutation in PGRN and underlying FTLD-U with NII neuropathologic abnormalities. This finding is in distinct contrast to previously reported kindreds, in which clinical presentations have typically been within the spectrum of FTLD. The basis for the large difference in age at onset between generations requires further study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20142525      PMCID: PMC2902004          DOI: 10.1001/archneurol.2010.113

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  22 in total

1.  Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22.

Authors:  S M Rosso; W Kamphorst; B de Graaf; R Willemsen; R Ravid; M F Niermeijer; M G Spillantini; P Heutink; J C van Swieten
Journal:  Brain       Date:  2001-10       Impact factor: 13.501

2.  Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations.

Authors:  Keith A Josephs; Zeshan Ahmed; Omi Katsuse; Joseph F Parisi; Bradley F Boeve; David S Knopman; Ronald C Petersen; Peter Davies; Ranjan Duara; Neill R Graff-Radford; Ryan J Uitti; Rosa Rademakers; Jennifer Adamson; Matthew Baker; Michael L Hutton; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2007-02       Impact factor: 3.685

3.  Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families.

Authors:  Marsel Mesulam; Nancy Johnson; Thomas A Krefft; Jennifer M Gass; Ashley D Cannon; Jennifer L Adamson; Eileen H Bigio; Sandra Weintraub; Dennis W Dickson; Michael L Hutton; Neill R Graff-Radford
Journal:  Arch Neurol       Date:  2007-01

4.  HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin.

Authors:  Odity Mukherjee; Pau Pastor; Nigel J Cairns; Sumi Chakraverty; John S K Kauwe; Shantia Shears; Maria I Behrens; John Budde; Anthony L Hinrichs; Joanne Norton; Denise Levitch; Lisa Taylor-Reinwald; Michael Gitcho; P-H Tu; Lea Tenenholz Grinberg; Rajka M Liscic; Javier Armendariz; John C Morris; Alison M Goate
Journal:  Ann Neurol       Date:  2006-09       Impact factor: 10.422

5.  Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations.

Authors:  Jennifer L Whitwell; Clifford R Jack; Matthew Baker; Rosa Rademakers; Jennifer Adamson; Bradley F Boeve; David S Knopman; Joseph F Parisi; Ronald C Petersen; Dennis W Dickson; Michael L Hutton; Keith A Josephs
Journal:  Arch Neurol       Date:  2007-03

6.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease.

Authors:  G M McKhann; M S Albert; M Grossman; B Miller; D Dickson; J Q Trojanowski
Journal:  Arch Neurol       Date:  2001-11

7.  Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family.

Authors:  Yoshio Tsuboi; Ryan J Uitti; Marie-Bernadette Delisle; Joaquim J Ferreira; Christine Brefel-Courbon; Olivier Rascol; Bernardino Ghetti; Jill R Murrell; Michael Hutton; Matthew Baker; Zbigniew K Wszolek
Journal:  Arch Neurol       Date:  2002-06

8.  Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study.

Authors:  Bradley F Boeve; Matt Baker; Dennis W Dickson; Joseph E Parisi; Caterina Giannini; Keith A Josephs; Michael Hutton; Stuart M Pickering-Brown; Rosa Rademakers; David Tang-Wai; Clifford R Jack; Kejal Kantarci; Maria M Shiung; Todd Golde; Glenn E Smith; Yonas E Geda; David S Knopman; Ronald C Petersen
Journal:  Brain       Date:  2006-10-09       Impact factor: 13.501

9.  Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome.

Authors:  Mario Masellis; Parastoo Momeni; Wendy Meschino; Reid Heffner; Joshua Elder; Christine Sato; Yan Liang; Peter St George-Hyslop; John Hardy; Juan Bilbao; Sandra Black; Ekaterina Rogaeva
Journal:  Brain       Date:  2006-10-09       Impact factor: 13.501

10.  Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration.

Authors:  Jennifer Gass; Ashley Cannon; Ian R Mackenzie; Bradley Boeve; Matt Baker; Jennifer Adamson; Richard Crook; Stacey Melquist; Karen Kuntz; Ron Petersen; Keith Josephs; Stuart M Pickering-Brown; Neill Graff-Radford; Ryan Uitti; Dennis Dickson; Zbigniew Wszolek; John Gonzalez; Thomas G Beach; Eileen Bigio; Nancy Johnson; Sandra Weintraub; Marsel Mesulam; Charles L White; Bryan Woodruff; Richard Caselli; Ging-Yuek Hsiung; Howard Feldman; Dave Knopman; Mike Hutton; Rosa Rademakers
Journal:  Hum Mol Genet       Date:  2006-09-01       Impact factor: 6.150

View more
  25 in total

1.  Frontotemporal dementia-related gene mutations in clinical dementia patients from a Chinese population.

Authors:  Zhihong Shi; Shuai Liu; Lei Xiang; Ying Wang; Mengyuan Liu; Shuling Liu; Tong Han; Yuying Zhou; Jinhuan Wang; Li Cai; Shuo Gao; Yong Ji
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

2.  An algorithm for genetic testing of frontotemporal lobar degeneration.

Authors:  J S Goldman; R Rademakers; E D Huey; A L Boxer; R Mayeux; B L Miller; B F Boeve
Journal:  Neurology       Date:  2011-02-01       Impact factor: 9.910

Review 3.  Human genetics as a tool to identify progranulin regulators.

Authors:  Alexandra M Nicholson; NiCole A Finch; Rosa Rademakers
Journal:  J Mol Neurosci       Date:  2011-05-28       Impact factor: 3.444

4.  Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.

Authors:  Hideyuki Takahashi; Zoe A Klein; Sarah M Bhagat; Adam C Kaufman; Mikhail A Kostylev; Tsuneya Ikezu; Stephen M Strittmatter
Journal:  Acta Neuropathol       Date:  2017-01-09       Impact factor: 17.088

5.  Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.

Authors:  Ramón Cacabelos; Rocío Martínez; Lucía Fernández-Novoa; Juan C Carril; Valter Lombardi; Iván Carrera; Lola Corzo; Iván Tellado; Jerzy Leszek; Adam McKay; Masatoshi Takeda
Journal:  Int J Alzheimers Dis       Date:  2012-03-14

6.  C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic.

Authors:  Aleksandra Wojtas; Kristin A Heggeli; Nicole Finch; Matt Baker; Mariely Dejesus-Hernandez; Steven G Younkin; Dennis W Dickson; Neill R Graff-Radford; Rosa Rademakers
Journal:  Am J Neurodegener Dis       Date:  2012-05-16

7.  C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease.

Authors:  Matthew Harms; Bruno A Benitez; Nigel Cairns; Breanna Cooper; Paul Cooper; Kevin Mayo; David Carrell; Kelley Faber; Jennifer Williamson; Tom Bird; Ramon Diaz-Arrastia; Tatiana M Foroud; Bradley F Boeve; Neill R Graff-Radford; Richard Mayeux; Sumitra Chakraverty; Alison M Goate; Carlos Cruchaga
Journal:  JAMA Neurol       Date:  2013-06       Impact factor: 18.302

Review 8.  Alzheimer's disease genetics: from the bench to the clinic.

Authors:  Celeste M Karch; Carlos Cruchaga; Alison M Goate
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

Review 9.  Progranulin: an emerging target for FTLD therapies.

Authors:  Jennifer Gass; Mercedes Prudencio; Caroline Stetler; Leonard Petrucelli
Journal:  Brain Res       Date:  2012-01-28       Impact factor: 3.252

10.  The GGGGCC repeat expansion in C9ORF72 in a case with discordant clinical and FDG-PET findings: PET trumps syndrome.

Authors:  Anahita Adeli; Rodolfo Savica; Val J Lowe; Prashanthi Vemuri; David S Knopman; Mariely Dejesus-Hernandez; Rosa Rademakers; Julie A Fields; Brian A Crum; Clifford R Jack; Ronald C Petersen; Bradley F Boeve
Journal:  Neurocase       Date:  2012-11-30       Impact factor: 0.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.